|Day Low/High||159.57 / 161.15|
|52 Wk Low/High||114.27 / 197.00|
Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.
Net income increases to EUR 618 million reflecting realized gains and lower other charges ● Underlying earnings decrease by 5% to EUR 1,010 million, reflecting lower fee income as a result of lower average asset balances in the US, and investments in the...
EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.
Aegon announces that its Supervisory Board intends to propose the appointment of Lard Friese as Chief Executive Officer to the Annual General Meeting of Shareholders.
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.
- Q2 2019 GAAP Net Revenues of $4.09 Billion -
A timeline of how Botox became one of the most popular medical beauty procedures.
U.S. stock futures rise Tuesday, following Wall Street's worst day of the year, as China attempts to ease trade tensions with the U.S., Walt Disney to report earnings Tuesday; Barneys New York files for bankruptcy protection.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
While you may think earnings season is winding down, we still got quite a bit left to go ... here are key companies to keep an eye on the week of August 5, 2019.
Aegon has completed the share buyback program announced on June 19, 2019. This program neutralized the dilutive effect of the 2018 final dividend paid in shares.
DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.
Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Actress encourages women to take active roles in their reproductive health, including researching birth control options
Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.
-- Global Action Follows Notification of Updated Safety Information from the U.S.
U.S. stock futures are lower as U.S.-China trade talks are set to resume; the Department of Justice launches a new probe into whether Alphabet, Amazon, Facebook and Apple have been stifling competition; Tesla, Boeing, Ford, Facebook and Caterpillar report earnings.
- Dividend to be Paid on September 13, 2019 -
First Biosimilar Avastin® and Herceptin® Products to Launch in the United States
A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman.
-- Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost Sustained-Release --
Here are my five rules for handling earnings season.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, BPFH, TRTN Downgrades: HMG, PIH Initiations: DHXM Read on to get TheStreet Quant Ratings' detailed report:
Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.